BioQ Pharma news

BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced receipt of CE mark approval in the European Union for its OneDose ReadyfusOR Gen2, single-use medication dispenser. The OneDose ReadyfusOR Gen2 is the second generation of the Company’s original OneDose ReadyfusOR infusion system and was developed to further improve patient convenience. The new OneDose ReadyfusOR Gen2 comes in a smaller size and with a significant weight reduction c

BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced that Dr. Marijn Dekkers has agreed to join the Company’s board of directors.

Dr. Dekkers is founder and chairman of Novalis LifeSciences, an investment and advisory firm for the life science industry. He served as CEO of Bayer AG, a global life sciences company, from 2010 to 2016 and as CEO of Thermo Fisher Scientific Inc., a global leader in the manufacturing of laboratory

BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced that it has entered into a Development, Supply, Distribution Agreement with Avanos Medical, Inc. (NYSE: AVNS, “Avanos”). Under the agreement, the parties will work together to obtain appropriate regulatory approvals and commercialize self-contained, infusible, non-opioid post-operative pain pharmaceutical product in the United States, Canada and Mexico.

Avanos, which established the iconic On-Q b

BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Propofusor product containing 1% propofol in a single-use dispensing system. Uses of the Propofusor include the induction and maintenance of general anesthesia, sedation of mechanically ventilated adults in intensive care, and conscious sedation during diagnostic and surgical procedures. With an es

BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals, today announced the positive closure of a European regulatory procedure for its propofol product. The Company’s ready-to-use infusion pharmaceutical includes the propofol drug product and delivery system in a single-use unit-dose presentation.

The European countries involved in this regulatory procedure will no